Gefitinib in pretreated non-small-cell lung cancer (NSCLC):: Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC
Gefitinib in pretreated non-small-cell lung cancer (NSCLC):: Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC
复制标题
DOI：
10.1200/jco.2003.01.039
复制
发表时间：
2003-07-15
影响因子：
45.3
通讯作者：
Crinò, L
中科院分区：
文献类型：
--
作者：
Cappuzzo, F;Gregorc, V;Crinò, L
目的：评估 HER2 表达与吉非替尼（ZD 1839，易瑞沙；阿斯利康，伦敦，英国）在缓解率、进展时间 (TTP) 和总生存 (OS) 时间方面的疗效之间的相关性。 患者和方法：已接受过治疗的晚期非小细胞肺癌 (NSCLC) 患者接受每日剂量 250 mg 的吉非替尼治疗，直至疾病进展。收集初次诊断时获得的肿瘤组织标本，通过免疫组织化学测定HER2/表皮生长因子受体（EGFR）状态。结果：从2001年2月至2002年6月，连续63名患者入组研究。总体疾病控制率为58.70%（部分缓解[PR]，15.9%；疾病稳定[SD]，42.8%），中位TTP为3.3个月，中位OS为4.1。几个月。在确定 EGFR/HER2 状态的 43 名患者中，我们观察到 6 例 PR（14%）和 18 例 SD（42%）。疾病控制（包括 PR 和 SD）在 15 名过度表达 HER2 的患者中为 40%，在 28 名不过度表达 HER2 的患者中为 64.3% (P = .126)。两组之间的 TTP（分别为 3.5 个月和 3.7 个月）和 OS（分别为 5.7 个月和 6.8 个月）没有差异。此外，与 HER2 不过度表达的患者相比，我们没有发现 HER2 和 EGFR 过度表达的患者组的 TTP、OS、毒性和症状结果有任何差异。结论：根据这些数据，接受吉非替尼治疗的 NSCLC 患者的疗效、毒性和症状结果似乎与 HER2 表达无关。 (C) 2003 年，美国临床肿瘤学会。
Purpose: To evaluate the correlation between HER2 expression and gefitinib (ZD 1839, Iressa; AstraZeneca, London, United Kingdom) efficacy in terms of response rate, time to progression (TTP), and overall survival (OS) time.Patients and Methods: Patients with pretreated advanced non-small-cell lung cancer (NSCLC) received gefitinib at a daily dose of 250 mg until disease progression. Tumor tissue specimens obtained at the time of primary diagnosis were collected to determine HER2/epidermal growth factor receptor (EGFR) status by immunohistochemistry.Results: From February 2001 to June 2002, 63 consecutive patients were enrolled onto the study. The overall disease control rate was 58.70% (partial response [PR], 15.9%; stable disease [SD], 42.8%), median TTP was 3.3 months, and median OS was 4.1. months. Among the 43 patients in whom EGFR/HER2 status was determined, we observed six PRs (14%) and 18 SDs (42%). Disease control, including PR and SD, was 40% in the 15 patients overexpressing HER2 and 64.3% in the 28 patients not overexpressing HER2 (P = .126). No difference was found between the two groups in terms of TTP (3.5 v 3.7 months, respectively) and OS (5.7 v 6.8 months, respectively). In addition, we did not find any difference in TTP, OS, toxicity, and symptom outcome in the group of patients overexpressing both HER2 and EGFR compared with patients who had no overexpression of HER2Conclusion: According to these data, efficacy, toxicity, and symptom outcome in patients with NSCLC treated with gefitinib do not seem to be related to HER2 expression. (C) 2003 by American Society of Clinical Oncology.